Liver InjuriesNCT06758908
Prevelance, Predictors and Outcome of Sepsis Associated Liver Injury (SALI)
An observational study of Liver Injuries, run by Assiut University.
Trial summary
prevelance, predictors and outcome of sepsis associated liver injury (SALI) Read more about this study
- Who is it for?
- Ages 15 to 75 years
- Conditions the study is for
- Liver Injuries
- What is being tested?
- Antibiotic
- Type of treatment
- Medical device
- How many people
- 100 participants
- Where
- No sites listed yet
- Study dates
- Apr 2025to Oct 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 15 to 75 years
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: all people between 15 to 75 years
Who may be able to join
- clinical diagnosis of SALI
- must take liver support
Who cannot join
- SALI
- Thyroid disease
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
prevelance, predictors and outcome of sepsis associated liver injury (SALI)
Read the detailed description
patient with liver disease and sepsis at the same time
- Conditions
- Liver Injuries
- Being tested
- Antibiotic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AntibioticDevice
SALI
| Study group | Role | What they receive |
|---|---|---|
| SALI | Not described Receives: Device: Antibiotic |
What is being measured
The primary outcome is the main question the study is designed to answer.
prevelance, predictors and outcome of sepsis associated liver injury (SALI)
analysis outcome of sepsis associated liver injury (SALI)
Measured: baseline
28 days mortality
patient with liver dieases and sepsis
Measured: baseline
patient shouldn't be in pain
patient in study not in pain
Measured: baseline
Secondary outcomes (1)
patient stay in hospital 2weeks
patient with liver dieases and sepsis
Measured: baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Jan 2025
- Study startApr 2025 (estimated)
- Primary completionSep 2026 (estimated)
- Study completionOct 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Liver InjuriesStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Collaborators
- Investigator
- Responsible party
- Principal investigator, Mahmoud sayed Zohry Sayed, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06758908
- Sponsor's protocol ID
- prevelance ,predictors of SALI
- Status last verified
- Dec 2024
- First submitted
- 14 Dec 2024
- Last updated
- 6 Jan 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 6 Jan 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prevelance, Predictors and Outcome of Sepsis Associated Liver Injury (SALI)
- ClinicalTrials.gov ID
- NCT06758908
- Acronym / sponsor ID
- prevelance ,predictors of SALI
- Conditions
- Liver Injuries
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Collaborators
- Investigator
- Study start
- Apr 2025 (estimated)
- Primary completion
- Sep 2026 (estimated)
- Study completion
- Oct 2026 (estimated)
- First posted
- 6 Jan 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
prevelance, predictors and outcome of sepsis associated liver injury (SALI)
Detailed description
patient with liver disease and sepsis at the same time
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| SALI | – | Device: Antibiotic |
Who may qualify
- Ages
- 15 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- all people between 15 to 75 years
Key inclusion criteria (2 listed)
- clinical diagnosis of SALI
- must take liver support
Key exclusion criteria (2 listed)
- SALI
- Thyroid disease
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| AntibioticSALI | Device | SALI |
Primary outcome
prevelance, predictors and outcome of sepsis associated liver injury (SALI)
Time frame: baseline
analysis outcome of sepsis associated liver injury (SALI)
28 days mortality
Time frame: baseline
patient with liver dieases and sepsis
patient shouldn't be in pain
Time frame: baseline
patient in study not in pain
1 secondary outcome
patient stay in hospital 2weeks
Time frame: baseline
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Jan 2025.
- Individual participant dataSharing planned: No
Related trials for Liver Injuries
Not yet recruiting
Vitamin C for Acute Kidney Injury in ACLF With Septic Shock: A Randomized Controlled Trial
Acute-on-Chronic Liver Failure (ACLF)
Not yet recruitingPhase 2
SAMe in Prevention of Oxaliplatin-associated Liver Injury
Colorectal Cancer, Liver Metastases
Not yet recruiting
New Biomarkers for Organ Viability Assessment During Hypothermic Machine Perfusion in Liver Transplantation: the Role of Extemporaneous Histological Examination.
Liver Transplantation (LT), Early Allograft Dysfunction
Recruiting
Avoiding Recooling After Normothermic Machine Perfusion in Liver Transplantation
Liver Transplantation (LT), Ischemia-Reperfusion Injury
RecruitingObservational study
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Rare Disorders, Undiagnosed Disorders
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
An observational study of Liver Injuries, run by Assiut University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 6 Jan 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Mahmoud sayed zohry, first mastar (01225463889 ext. 01069209843, mzohry789@yahoo.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
prevelance, predictors and outcome of sepsis associated liver injury (SALI) (time frame: baseline). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Jan 2025.